4.7 Article

Delta opioid receptors on nociceptive sensory neurons mediate peripheral endogenous analgesia in colitis

Journal

JOURNAL OF NEUROINFLAMMATION
Volume 19, Issue 1, Pages -

Publisher

BMC
DOI: 10.1186/s12974-021-02352-3

Keywords

Visceral pain; Opioid receptors; Nociceptors; T lymphocytes; Opioids; Intestinal inflammation

Funding

  1. French government through the Investments for the Future program [ANR-11-EQPX-0003]
  2. INFINITy cellular imaging core facility

Ask authors/readers for more resources

This study identifies the important role of the delta opioid receptor (DOR) in relieving intestinal inflammatory pain and suggests the potential of developing peripherally restricted DOR analgesics for intestinal disorders, which could avoid the side effects associated with drugs targeting the mu opioid receptor (MOR).
Background Inflammatory visceral pain is endogenously controlled by enkephalins locally released by mucosal CD4(+) T lymphocytes in mice. The present study aimed at identifying opioid receptor(s) expressed on nociceptive sensory nerves involved in this peripheral opioid-mediated analgesia. Methods The peripheral analgesia associated with the accumulation of CD4(+) T lymphocytes within the inflamed colonic mucosa was assessed in conditional knockout mice specifically deleted for either of the two opioid receptors for enkephalins (i.e., mu (MOR) and delta (DOR) receptors) in Na(v)1.8-expressing sensory neurons in the dextran sulfate sodium (DSS)-induced colitis model. Results Endogenous analgesia is lost in conditional knockout mice for DOR, but not MOR at the later phase of the DSS-induced colitis. The absence of either of the opioid receptors on sensory nerves had no impact on both the colitis severity and the rate of T lymphocytes infiltrating the inflamed colonic mucosa. Conclusion The key role of DOR on primary afferents in relieving intestinal inflammatory pain opens new therapeutic opportunities for peripherally restricted DOR analgesics to avoid most of the side effects associated with MOR-targeting drugs used in intestinal disorders.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available